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Abstract National Institute of Neurological Disorders and Stroke sponsored a meeting
to explore the current status of basic and clinical research in peripheral neurobiology and
clinical neuropathy. The goal of the workshop was to identify areas where additional
research could lead to the development of new therapeutics in the next 5 years. Par-
ticipants discussed the current understanding of disease mechanisms of axonal and
demyelinating neuropathies, existing techniques in research, disease biomarkers, and
assessment of neuropathy. Painful neuropathies were discussed at the basic scientific
and clinical levels in relation to new insights into etiology and treatment. The meeting con-
cluded with a discussion on therapeutic development in neuropathy and the need for a
unified approach to multicenter trials. Short-term goals of the workshop were to form
a working group for neuropathy, the Peripheral Neuropathy Study Group, and to translate
new scientific findings into therapies and complete clinical trials.
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Introduction
On 22–24 October 2006, the National Institute of
Neurological Disorders and Stroke (NINDS) sponsored
a workshop to review the current state of basic sci-
ence and clinical investigation in the field of neuropa-
thy. The 60 attendees were charged with identifying
the major scientific gaps in neuropathy research with the
goal of accelerating research toward the development
of new therapies for patients. The workshop reviewed
the current understanding of disease mechanisms in
neuropathy and the accepted standards for diagnosis
in human and rodent models and explored new re-
search areas in neuropathic pain, biomarkers, and
technologies for the diagnosis of neuropathy. The
need to expand therapeutic development and com-
plete multicenter, standardized clinical trials was high-
lighted at the conclusion of the workshop. In this
meeting summary, six areas of interest are discussed
separately: disease mechanisms underlying axonal
and demyelinating neuropathies, neuropathic pain,
diagnosis of neuropathy and biomarkers, therapeutic
development, and clinical trials. Each section ends with
a list of major unanswered basic and clinical questions
that require further investigation. Throughout the
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workshop, the attendees made clear the important in-
terplay of these areas. A summary of the meeting high-
lights can be found on the NINDS website at http://
www.ninds.nih.gov/news_and_events/proceedings/10_
2006_NIH_Peripheral_Neuropathy_Conference.htm. A
complete document with more thorough discussions
of each area and details on each research objective
can be found on the NINDS website at http://www.
ninds.org.
Neuropathy
Neuropathy is one of the leading causes of dis-
ability in adults in the United States. Current studies
suggest that 20 million Americans are afflicted with
neuropathy, with significant individual morbidity and
societal costs. Neuropathy is currently characterized by
a spectrum of symptoms and signs that reflect anatom-
ical damage to the peripheral nervous system (PNS)
and dysfunction of normal nerve physiology. Despite
the prevalence of neuropathy, a basic understanding of
disease mechanisms and effective therapeutics are still
lacking. The workshop began with an evening session
by Drs. Peter Dyck, Stefano Previtali, and Baldomero
Olivera who highlighted the lack of effective therapies
for peripheral neuropathy, particularly painful neuropa-
thy, emphasizing the need to use disease-based mech-
anistic targets for therapeutic development.
Clinically, neuropathy has been traditionally divided
into axonal and demyelinating neuropathies, reflecting
the major anatomical pathology observed, although
most neuropathies over time exhibit both patholo-
gies. The workshop reconvened with a discussion of
neuropathies, based on this division, with the goal of
identifying the areas in basic research that could be
translated into meaningful therapies.
Axonal neuropathies
Dr. Jack Griffin opened the session by stating that
acute axonal degeneration, also known as Wallerian
degeneration, and more chronic axonal degeneration
are the most frequent pathologies observed in neuro-
pathy. Yet, little is known about the ionic, molecular, and
cellular changes responsible for the well-documented
length-dependent loss of axonal integrity and function
in both acute and chronic neuropathies. Dr. Zhigang He
summarized his work using the Wallerian degeneration
slow mice, a genetic model of slowed axonal degene-
ration. NAD levels decrease in degenerating axons, and
preventing this axonal NAD decline protects axons
from degeneration, emphasizing the importance of
local energy reserves for axonal health. Dr. Peter Stys
continued on the theme of the importance of energy
reserves. In normal nerves, ATP-dependent pumps
support the ionic gradient needed for axonal health.
When the energy supply is disrupted, ion gradients
break down, Naþ enters axons, promoting Naþ over-
load and depolarization and stimulates reverse Naþ-
Caþþ exchange, leading to further Caþþ entry. Energy
failure also promotes Caþþ release from intracellular
stores and releases potentially injurious neuro-
transmitters such as glutamate. Collectively, this Caþþ
overload inappropriately stimulates a variety of Caþþ-
dependent enzyme systems (e.g., calpains, phospholi-
pases), leading to structural and functional axonal
injury. Dr. Griffin concluded the session by highlighting
the lack of detailed knowledge of basic mechanisms of
Wallerian degeneration and the important interplay
between the axon and the Schwann cell during this
process. At each step, growth factors are required, yet
their therapeutic potential has not been fully realized.
The workshop attendees concluded that there are
six broad areas of research where more investigative
work would lead to new therapeutics in axonal neu-
ropathies, which are the following:
d Molecular events underlying Wallerian degeneration
and slowly progressive axonopathies.
d Regulation of axonal transport and the dysregulation
in neuropathies.
d Energy metabolism in the cell body and axons.
d Cation entry and channel function in acute and
chronic axonal injury.
d Interaction between the Schwann cell and the axon
during axonopathy.
d Growth factors as therapeutics to prevent chronic
axonal loss and/or promote regeneration.
Demyelinating neuropathies
Demyelinating neuropathies are due to a disruption
of Schwann cell function and are a subject of intense
scientific interest. Dr. James Salzer began the session
by reviewing the current understanding of the sequen-
tial steps involved in PNS myelination. In the transition
from premyelinating to myelinating Schwann cells,
multiple transcription factors are sequentially activated.
This transcription factor cascade is regulated by the
membrane-bound neuregulin (NRG)-1 type III isoform,
an axonal ligand for glial ErbB tyrosine kinase re-
ceptors. The amount of NRG expressed by axons dic-
tates the level of Schwann cell myelination during
development. In contrast, adult Schwann cells are not
dependent on NRG signaling through ErbB for pro-
liferation and survival after nerve injury. This novel find-
ing suggests that dedifferentiation of Schwann cells
during Wallerian degeneration may reflect a release of
an injury signal, not a loss of an axonal signal. Dr. Elior
Pelez discussed the intricate organization of Schwann
cell myelin. Tight, gap, and adherens junctions are
present between myelin lamellae in specialized regions
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of noncompact myelin. These junctions are called auto-
typic junctions. Heterotypic junctions occur between
Schwann cells and axons along the length of the axon
and at the node of Ranvier. The node of Ranvier is
highly organized into distinct regions that include the
nodes, paranodes, and juxtaparanodal regions. Each
area consists of a unique set of adhesion molecules,
ion channels, and cell surface proteins. Cell adhesion
molecules help dock ion channels in the correct posi-
tion. Demyelination disrupts the organization of ion
channels, leading to conduction slowing and/or block
and possibly contributing to the axonal loss that is
found in demyelinating diseases. Dr. Steven Scherer
concluded the session by discussing basic and clinical
questions about demyelinating neuropathies. He spec-
ulated that inherited demyelinating neuropathies are
common because the complexity of myelin renders it
vulnerable to a large number of genetic lesions.
Whereas the genes that cause most forms of inherited
demyelinating neuropathies have been discovered, the
structure and function of the proteins they encode are
largely unknown. Understanding these issues, includ-
ing the effects of mutations, are key questions that
need to be answered in order to develop treatments
based on disease mechanisms. Dr. Scherer concluded
with a discussion of the acquired demyelinating neu-
ropathies, emphasizing the important but little under-
stood role of immune-mediated attack of Schwann
cells as the inciting event.
The workshop attendees discussed seven broad
areas where additional research would translate into
new therapies for demyelinating neuropathies, which
are the following:
d Understanding why axonal loss occurs in demyelin-
ating neuropathies.
d Determining the effect of demyelination and re-
myelination on the function of myelinated axons.
d Understanding how mutant myelin proteins produce
demyelination.
d Identifying additional genetic causes of demyelinat-
ing neuropathies.
d Developing animal models that mimic the human
diseases.
d Determining the biological role of inflammatory cells
in inherited and acquired demyelinating neuropathies.
d Using genomic approaches to uncover disease-
modifying genes that alter the phenotype of in-
herited neuropathy or the susceptibility to acquired
demyelinating neuropathies.
Neuropathic Pain
Dr. Claudia Sommer introduced the topic of neuro-
pathic pain – defined as heightened sensitivity to nox-
ious (hyperpathia) or ordinarily non-noxious (allodynia)
stimuli as well as spontaneous pain. Neuropathic pain
is particularly associated with certain small-fiber neu-
ropathies and with specific types of nerve injury such
as postherpetic neuralgia. Neuropathic pain is com-
mon and takes a large personal and societal toll. The
pathogenesis of painful neuropathies is not well under-
stood. Potential mechanisms include spontaneous C
fiber nociceptor activity, inflammation with enhanced
cytokine production, and loss of large myelinated fibers.
Dr. Gary Bennett reviewed the animal models com-
monly used to study painful neuropathy. These include
animal models of diabetes (rats with streptozotocin-
induced diabetes and two genetic models of diabetes –
the non-obese diabetic mouse and the obese sand rat),
which is the most common cause of painful neuropathy
in humans. Chronic constriction and nerve root ligation
are models of post-traumatic painful neuropathy. Can-
cer in rodents can produce a degeneration of the very
distal sensory terminals, simulating the pathology seen
with certain cancers. Work in the various animal models
has shed light on potential pain mechanisms, including
abnormal spontaneous C fiber activity, central nervous
system (CNS) sensitization, disruption of CNS descend-
ing inhibitory and excitatory pathways, loss of spinal
cord segmental inhibitor control, and disruption of nor-
mal neuroimmunomodulatory pathways. Dr. Clifford
Woolf introduced the idea of a genetic basis of peri-
pheral neuropathic pain perception. Several known
inherited pain syndromes are due to one or more
point mutations. For example, some mutations in
the gene encoding Nav 1.7, one of the voltage-
gated sodium channels, result in spontaneous neu-
ropathic pain, while mutations in a variety of other
genes (SPTLC1, HSN2, IKBKAP, TRKA, NGFB) re-
sult in diminished perception of pain. There are sev-
eral candidate genes that may determine differential
sensitivity to pain, including those encoding cate-
chol-O-methyltransferase, melanocortin-1 receptor,
guanosine triphosphate cyclohydrolase, and the mu-
opioid receptor. Polymorphisms in these or other
pain ‘‘targets’’ could affect an individual’s threshold
to pain, leading to the key question: Is the percep-
tion of neuropathic pain a heritable trait? To answer
this question, genome-wide scanning would need to
be performed on large cohorts of carefully pheno-
typed patients. This could enable the identification
of individuals at risk for developing neuropathic pain
and novel targets for treating pain.
The workshop attendees discussed seven broad
areas in which additional research could be translated
into new therapies for painful neuropathies, which are
the following:
d Develop new animal models of clinically relevant
neuropathic pain.
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d Identify the mechanisms that generate spontaneous
discharges in injured somatosensory primary afferent
neurons.
d Investigate the role of C fibers and their associated
Schwann cells in animal and human models of neu-
ropathic pain.
d Identify the key changes in the spinal cord dorsal
horn for the genesis and maintenance of painful
peripheral neuropathy.
d Define the role of cytokines, chemokines, and
inflammatory mediators in inflammatory neuropathic
pain in the PNS and spinal cord.
d Conduct whole-genome haplotype analyses of pa-
tients with defined neuropathic pain syndrome to
validate existing and identify new pain targets.
d Form a collaborative research consortium of pain
specialists to perform large-scale epidemiology stu-
dies of painful neuropathy and to develop practical
clinical assessment tools.
Neuropathy Diagnosis and Biomarker
Development
Biomarkers are needed to predict and assess
severity of neuropathy. Dr. Michael Polydefkis began
the session by reviewing the evidence that measure-
ments of intraepidermal nerve fiber (IENF) densities
from skin biopsies from patients with diabetes,
impaired glucose tolerance, and HIV neuropathy are
important and clinically relevant. IENF densities are
a quantitative measurement of cutaneous innervation,
appear to measure disease progression, and may
have a role in demonstrating improvement with ther-
apy as demonstrated by the capsaicin model. This
model uses serial skin biopsies after topical capsaicin
application (which denervates the epidermis) to mea-
sure sprouting of epidermal fibers. Sprouting is
reduced in patients with diabetes, so that sprouting
after capsaicin treatment may correlate with the abil-
ity of axons to regenerate in humans. This technique
is currently in use in clinical trials to monitor the
response to drug therapy in diabetic and HIV neuropa-
thy. IENF swellings are a second potentially useful
feature; these may be a biomarker of early nerve fiber
dysfunction. Dr. Steven Vernino reviewed serological
assessments of neuropathy, emphasizing that most
available tests are markers of neuropathy but may not
be directly pathogenetic. Paraneoplastic antibodies
identify patients who have a malignancy-associated
neuropathy. One example is the sensory neuropathy/
neuronopathy associated with type 1 antineuronal an-
tibodies (also referred to as anti-Hu), usually associ-
ated with small-cell lung carcinoma. These antibodies
do not produce disease in animal models. Antibodies
against type 2 antineuronal antibody and collapsing-
response-mediating protein 5 are also associated with
neuropathy. Antibodies to gangliosides or glyco-
proteins are present in several sensory and motor neu-
ropathy syndromes. Commonly measured antibodies
include binding to GM1 ganglioside for multifocal motor
neuropathy and for Campylobacter jejuni–associated
Guillain-Barré syndrome, GQ1b ganglioside for Fisher
Syndrome, and myelin-associated glycoprotein for
chronic demyelinating neuropathy. Many of these
epitopes suggest a role for molecular mimicry and
implicate immune-mediated mechanisms in the path-
ogenesis of neuropathy. Dr. Phillip Low reviewed the
spectrum of electrophysiological tests that are used
to diagnose neuropathies, emphasizing small-fiber
neuropathies that are not measured in standard nerve
conduction studies. The spectrum of small-fiber neu-
ropathies includes distal autonomic, generalized auto-
nomic, and distal painful small-fiber neuropathy
(DSFN). The quantitative sudomotor axon reflex test
(QSART) measures sweat as an index of post-
ganglionic sudomotor denervation, while thermal sen-
sory testing (TST) quantitates responses to heat and
cold. Patients with DSFN had an abnormality of
QSART and/or TST, despite the fact that 75% had
normal standard nerve conduction studies. Unmyelin-
ated fibers (autonomic and somatic) appear to be
affected together in small-fiber neuropathies; there is
a relationship between norepinephrine levels and IENF
density and a corresponding relationship between
autonomic failure and IENF density.
The workshop attendees discussed four broad
areas where additional research would translate into
new avenues of biomarker development and diagno-
sis, which are the following:
d Define criteria for the diagnosis of specific large- and
small-fiber and autonomic neuropathies, both early
and later in the disease process, and the use of
serological tests.
d Identify robust tests for small-fiber function, including
skin biopsy and QSART, and establish national nor-
mative databases for these small-fiber function tests.
d Identify potential new biomarkers of nerve disease
and improve existing measures for use in trials of
interventions for peripheral nerve disease.
d Develop evidence-based algorithms for the evalua-
tion and monitoring of patients with neuropathy to
facilitate diagnosis and minimize unnecessary testing.
Therapeutic Development in Peripheral
Neuropathy
Dr. Douglas Zochodne began the session by intro-
ducing the idea that the role of dorsal root ganglion
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neurons as targets in neuropathy merits further study.
Injury to sensory ganglions could be the primary event
in many conditions. Dr. Ahmet Höke discussed the
idea that different mechanisms underlie axonal main-
tenance compared to axonal regeneration, raising
a series of yet unanswered questions: What are the
major protective pathways for axonal maintenance?
Are mechanisms of chronic distal axonal degeneration
similar or different than Wallerian degeneration? Are
terminal, periaxonal, and motor and sensory Schwann
cells different from one another? What impact does
this have on axonal maintenance, regeneration, and
motor/sensory axon specificity and regeneration to
the correct target? Advances in therapeutic develop-
ment will depend on more knowledge on these is-
sues. Drs. J. Robinson Singleton and Kurt Fischbach
discussed therapeutic development in demyelinating
neuropathies. Dr. Singleton opined that immunosup-
pressive strategies for acquired demyelinating neu-
ropathies will advance beyond current available
therapies after the disease targets have been investi-
gated at a cellular and molecular level, including the
ensuing inflammatory response. Dr. Fischbach out-
lined currently available options for treating hereditary
demyelinating neuropathies, including onapristone,
a progesterone antagonist, and ascorbic acid. He
speculated that additional breakthroughs would come
from new approaches such as interfering RNAs and
gene therapy to correct protein misfolding, modulat-
ing Schwann cell-axon signaling, and using stem cells
to replace defective Schwann cells. The session
ended with a discussion by Dr. Mark Scheidler on the
key research areas stimulating progress in therapy
development. These include drug assay development
with identification of lead compounds, animal disease
models enabling proof of principle studies, and trans-
lation of mechanisms and outcome measures to
human trials. Importantly, the National Institutes of
Health (NIH) has established drug screening centers
with shared chemical libraries that allow investigators
to identify drug targets of interest in their field; the
website for this initiative is http://nihroadmap.nih.gov/
molecularlibraries.
The workshop attendees discussed five broad
areas where additional research would translate into
new avenues of biomarker development and diagno-
sis, which are the following:
d Develop a platform for identifying therapeutic targets
of sensory and/or motor neuropathies, neuronopa-
thies, and axonopathies.
d Develop high-throughput screens for axonal pro-
tection or regeneration.
d Confirm emerging therapies based on identification
of new targets in appropriate animal models.
d Develop mechanism-based therapies for immune-
mediated neuropathies.
d Develop therapies for inherited demyelinating neuro-
pathies.
Clinical Trials in Neuropathy
The final session of the meeting focused on clini-
cal trials in neuropathy. Dr. Roy Freeman began the
session by emphasizing the importance of using novel
approaches in humans to bring mechanism-based
therapies into the clinic. Dr. David Cornblath outlined
the steps needed to develop a successful Clinical
Trials Group in neuropathy based on the successful
models in oncology (National Cancer Institute) and
AIDS (National Institute of Allergy and Infectious Dis-
ease). A multinational Central Steering and Planning
Group would decide priorities for research and clinical
trials and work closely with industry and regulatory
agencies. This Peripheral Neuropathy Study Group
(PNSG) would identify therapeutic priorities, establish
clinical guidelines, centralize clinical trial forms and
statistical support, and complete pivotal trials. The
PNSG would be formed with the assistance of
NINDS. Dr. Steve Goodman discussed novel designs
for clinical trials. These include Bayesian methods,
adaptive designs, prospective meta-analysis, enrich-
ment designs, patient preference, and dynamic treat-
ment designs. While all these new approaches hold
appeal for innovative trials in neuropathy, a clinical trial
using an enrichment design could provide an initial tri-
al structure for the proposed PNSG. In this trial
design, patients enrolled are those who are early in
their disease and are most likely to show an effect of
therapy. All patients are treated and initial response is
evaluated by a surrogate marker (e.g., regenerative
response in the capsaicin paradigm). Those patients
who exhibit either positive or neutral effects are ran-
domized. Dr. Joseph Arezzo emphasized that there
are currently no well-defined, universally accepted
clinical endpoints for neuropathy trials. Studies use
a wide range of outcome measures. Standardization
of a select group of measures would allow improved
comparisons between trials.
The workshop attendees discussed seven broad
areas where additional research would translate into
new avenues of biomarker development and diagno-
sis, which are the following:
d Develop new designs and strategies for peripheral
neuropathy clinical trials.
d Develop improved approaches for selecting the
most appropriate patients for symptomatic, disease-
modifying, regenerative, and preventive clinical trials
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including trials using ‘‘surrogate’’ measures to refine
recruitment strategies.
d Conduct prospective studies to define the natural
history in concert with studies of pathophysiologic
mechanisms of the different peripheral neuropathies.
d Develop new outcome measures or improve exist-
ing outcome measures for use in trials of inter-
ventions for peripheral nerve disease.
d Identify therapeutic targets to use in the improved
trial designs.
d Conduct phase III studies of the efficacy, tolerability,
and safety of treatments using the identified new
trial designs and therapies.
d Develop an international consortium of clinical re-
searchers and basic scientists known as the PNSG
to execute and oversee the objectives of the clinical
trial session.
Summary
The NINDS workshop explored the current state
of basic science and clinical investigation in the field
of neuropathy. Major scientific opportunities were
identified in all aspects of neuropathy research, from
the most basic to the completion of phase III clinical
trials. The charge to the NINDS and the neuropathy
community is to develop programs to answer these
essential research questions. These programs should
include both basic and clinical investigations and the
establishment of an organized PNSG. A complete doc-
ument with more thorough discussions of each area
and details on each research objective can be found
on the NINDS website at http://www.ninds.org/.
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